Aligos Therapeutics, Inc. (NASDAQ:ALGS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) have earned an average rating of “Moderate Buy” from the five research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $41.50.

A number of analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aligos Therapeutics in a research note on Monday, April 20th. Jefferies Financial Group upgraded shares of Aligos Therapeutics to a “strong-buy” rating in a research report on Thursday, March 26th. Westpark Capital began coverage on shares of Aligos Therapeutics in a research report on Thursday, March 26th. They set a “buy” rating and a $48.00 target price on the stock. Wall Street Zen lowered shares of Aligos Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Finally, HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Aligos Therapeutics in a research report on Wednesday, March 11th.

More Aligos Therapeutics News

Here are the key news stories impacting Aligos Therapeutics this week:

• Positive Sentiment: Ten abstracts were accepted for EASL Congress 2026, giving Aligos a platform to showcase clinical and preclinical data across its liver and viral disease pipeline. Article Title
• Positive Sentiment: The breadth of programs highlighted, including pevifoscorvir sodium, ALG-170675, and ALG-055009, suggests continued pipeline momentum in high-unmet-need indications. Article Title

Aligos Therapeutics Stock Up 0.3%

ALGS opened at $6.69 on Friday. The firm has a market cap of $41.41 million, a P/E ratio of -0.77 and a beta of 2.28. Aligos Therapeutics has a 52 week low of $5.12 and a 52 week high of $13.69. The business’s fifty day simple moving average is $7.05 and its 200 day simple moving average is $8.04.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($2.21) EPS for the quarter, beating analysts’ consensus estimates of ($2.29) by $0.08. The business had revenue of $2.83 million for the quarter, compared to analyst estimates of $0.25 million. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%. As a group, equities analysts expect that Aligos Therapeutics will post -7.54 EPS for the current fiscal year.

Institutional Trading of Aligos Therapeutics

Hedge funds have recently bought and sold shares of the company. Woodline Partners LP purchased a new stake in Aligos Therapeutics in the 1st quarter valued at about $2,602,000. Marshall Wace LLP purchased a new stake in Aligos Therapeutics in the 4th quarter valued at about $2,504,000. SummitTX Capital L.P. purchased a new stake in Aligos Therapeutics in the 4th quarter valued at about $1,299,000. Verition Fund Management LLC purchased a new stake in Aligos Therapeutics in the 4th quarter valued at about $664,000. Finally, Readystate Asset Management LP grew its holdings in Aligos Therapeutics by 48.5% in the 3rd quarter. Readystate Asset Management LP now owns 203,113 shares of the company’s stock valued at $1,991,000 after buying an additional 66,331 shares during the period. Institutional investors and hedge funds own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small?molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.